Penumbra recently announced that it has received FDA 510(k) clearance for its Real Immersive virtual reality system. The Real Immersive System […]
Alcyone Lifesciences recently obtained Breakthrough Device Designation from the FDA for their novel implantable intrathecal bolus drug delivery catheter and port system, the ThecaFlex DRx System.
Brain-computer interfaces, those that could restore function in severely disabled people and give them ability to control robotic arms and other devices, depend on neural probes implanted into the brain. These technologies tend to work pretty well at first, but over time they draw attention of the surrounding immune system and the brain’s defensive mechanisms, resulting in inflammation, death of nearby neurons, and loss of functionality. Scientists at Harvard University have now created neural probes that mimic natural neurons, and thereby remain “under the radar” and avoid negative consequences.
Brian Harris is a board-certified music therapist. His work took him to Spaulding Rehabilitation Hospital in Boston, where he started the organization’s first Neurologic Music Therapy program. Harris was utilizing music to help patients improve their ability to walk, and it was working.
BrainScope said today that it completed a validation study of its BrainScope One device designed to assess head injuries, exploring its ability to assess mild traumatic brain injuries in adolescent and young adult populations.
A new U.S. Centers for Medicare & Medicaid Services trial of LivaNova‘s (NSDQ:LIVN) Vagus Nerve Stimulation Therapy system intended to treat treatment-resistant depression will require a sham-control arm, doubling the subject population LivaNova originally expected.
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device.
Cala Health said this week it inked a deal to license technology from Partners Healthcare and its affiliate Massachusetts General Hospital intended to improve the company’s non-invasive neuromodulation platform for investigating and treating chronic diseases.
A new study has found that NeurOptics’ NPi-200 pupillometer, which provides an automated assessment of the pupillary light reflex, may give an early warning of delayed cerebral ischemia, enabling preemptive care. The study was published in the Journal of Neurosurgery.